Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead 
Welcome,         Profile    Billing    Logout  
 0 Diseases   10 Trials   10 Trials   41 News 


«12...89101112131415161718...2627»
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Real-life monocentric Biktarvy cohort from Perugia () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_255;    
     Our results show the high effectiveness both in naïve (95%) and experienced patients (94.1%) including a small number (four) of individuals treated with M184V, adverse effect with treatment discontinuation was observed in 1.8% of cases. The discontinuation for any cause was 7.4%.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a single centre in Portugal () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_231;    
    Moreover, our data seem to support the idea that boosted regimens negatively influence the status of the immune system, not being able to completely tame the inflammatory stimulus caused by the HIV infection. The use of B/F/TAF in this real-world cohort supports the results from clinical trials, showing high rates of virological suppression and persistence at 6 and 12 months of follow-up.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
    Detection of 12-month immunological changes in patients randomised to switch either to BIC/TAF/FTC or DTG/3TC (DEBATE study) () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_226;    
    The aim of the present study was to evaluate, in a randomised longitudinal study, the immunological impact of switching to DTG/3TC or to bictegravir/emtricitabine/tenofovir alafenamide (BIC/TAF/FTC). In this randomised study, switch to DTG/3TC was associated after 12 months with an increase both in CD4+ and CD8+ T lymphocytes with markers related to terminal differentiation  and exhaustion, and in nonclassical monocytes, a population of cells that has been recently associated with endothelial dysfunction.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Switch to bictegravir in real-life settings in the ANRS-CO3-AquiVIH-NA cohort () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_224;    
    Virological failure was observed in 3% of patients. The switch to BIC/FTC/TAF in virologically suppressed patients is a safe and effective strategy.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label B/F/TAF () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_215;    
    These results provide additional long-term evidence of the safety and efficacy of B/F/TAF in those who switch from a DTG-containing regimen. aDefined as the last non-missing value obtained on or prior to the first dose of open-label B/F/TAF; bfrom time of B/F/TAF start.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    BICNOW clinical trial: preliminary results of rapid test and treat BIC/FTC/TAF study in naive PLWHIV () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_186;    
    BIC/FTC/TAF is a suitable option for the rapid initiation of ART in naïve individuals infected with HIV. Treatment was associated with a rapid reduction in viral load, significant increase in CD4 and small increase in weight, BMI, abdominal circumference, with TC/HDL ratio decreased.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare
    Real-world experience with the two-drug regimen dolutegravir and lamivudine in women with HIV: a systematic literature review () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_172;    
    Available real-world evidence for WLWHIV using DTG + 3TC supports results from phase III clinical trials, demonstrating high virologic effectiveness in this underrepresented group. The current paucity of real-world data underscores the identified need to recruit women into well-designed studies that assess outcomes beyond virologic effectiveness to properly address data gaps for WLWHIV.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV aged 65 years or older: W24 results of the BICOLDER study - IMEA 057 () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_166;    
    P4
    Materials and The BICOLDER study (NCT04222283) is a multicentric, prospective, single-arm study conducted in virologically controlled PLWHIV aged 65 years or older (PLWHIV 65+) who switched from a booster antiretroviral containing regimen, ritonavir or cobicistat, to B/F/TAF...At screening, 75% of the participants were receiving elvitegravir/cobicistat, and 25% a boosted PI-containing regimen... These results suggest that B/F/TAF is safe, effective in this elderly HIV population with a long history of HIV infection, multiple comorbidities and comedication.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Transplacental transfer of bictegravir versus dolutegravir in human placenta () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_135;    
    DTG is available in combination with either FTC and TAF, or abacavir and lamivudine...In clinical trials, BIC/FTC/TAF had high safety and better tolerability and non-inferior viral suppression than the DTG-containing regimen [4]...The transfer of DTG at concentration 3000 ng/mL in one perfusion was slower than that of antipyrine and BTC. However, more perfusions will be performed to better understand the transfer of BIC and DTG.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Impact of switch towards 3TC/dolutegravir on the intact and total viral reservoir in the Rumba study () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_121;    
    Preliminary investigations of this first head-to-head study suggest that HIV-1 reservoir dynamics are similar between Dovato® and Biktarvy® and that switch towards 3TC/dolutegravir does not increase the total or intact HIV-1 viral reservoir. Adjusted analyses are on-going and will be presented.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Enrollment closed, Trial completion date:  DYAD: Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF (clinicaltrials.gov) -  Sep 22, 2022   
    P4,  N=222, Active, not recruiting, 
    Efficient, humanizing, and holistic approaches to care in a multidisciplinary setting, coupled with rapid and free ART initiation, seemed to help alleviate patients' concerns, address their bio-psycho-social challenges, encourage their initial and sustained engagement with HIV care and treatment, and ultimately contribute to positive experiences. Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> May 2023
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens (clinicaltrials.gov) -  Sep 22, 2022   
    P4,  N=37, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> May 2023 Recruiting --> Completed | N=20 --> 37 | Trial completion date: Apr 2023 --> May 2022 | Trial primary completion date: Apr 2023 --> May 2022
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    A RARE CASE OF INTRA- AND EXTRAHEPATIC CHOLESTASIS IN A PATIENT WITH KAPOSI SARCOMA (Convention Center Exhibit Hall: Rapid Area 2B) -  Sep 11, 2022 - Abstract #CHEST2022CHEST_4184;    
    With continued improvement of HIV treatment, incidence of HIV-associated KS has reduced significantly. However, in patients without treatment or interrupted therapy like our patient, especially those with AIDS, high level of suspicion should be maintained for timely diagnosis and treatment and avoiding future complications.
  • ||||||||||  Symfi (efavirenz/lamivudine/tenofovir disoproxil fumarate) / Mylan, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Rapid ART initiation using BIC/FTC/TAF and TDF+3TC+EFV in people with HIV in China: a randomised control trial () -  Sep 6, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_57;    
    This study analysed efavirenz 400 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg (EFV+3TC+TDF) and bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for efficacy and safety. These results suggested that BIC/FTC/TAF was safe and effective in rapid ART.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
    Iso Painful in My Belli (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_3775;    
    His HIV regimen was adjusted from Descovy and Prezcovix to Biktarvy for concern for resistance and nonadherence...It is more common in developing countries such as India and sub-saharan Africa and is rarely diagnosed in the United States. Thus, Isospora is not commonly part of the regular stool ova and parasite culture set and should be tested for in patients with high clinical suspicion.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    A Rare Case of Esophageal Kaposi Sarcoma Causing Dysphagia (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_3284;    
    Patient was treated with Bictegravir, emtricitabine and tenofovir alafenamide...Systemic therapy with liposomal anthracyclines is recommended for patients with advanced or rapidly progressive disease. Figure: Kaposi Sarcoma Lesions
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Don’t Forget the Gut: A Case of Gastrointestinal Kaposi Sarcoma (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_1397;    
    In the past two years, he was started on Bictegravir/emtricitabine/tenofovir alafenamide but was non-compliant...Gastric lesions Figure 1c. Rectal lesions
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    AIDS Cholangiopathy Secondary to Kaposi Sarcoma: A Rare Presentation (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_854;    
    Home medications included bictegravir/emtricitabine/tenofovir( Biktarvy) which was started approximately 6 weeks before hospitalization...Our patient most likely developed KS due to non-adherence to ART. Figure: MRI abdomen with contrast showed dilation of intrahepatic bile ducts and possible filling defects in the common bile duct.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    New trial, Metastases:  AHORA: Advanced HIV: Outcomes for Rapid ART (clinicaltrials.gov) -  Sep 2, 2022   
    P=N/A,  N=50, Not yet recruiting,